Abstract Library

#1582 Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors

Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Miki M, Ito T, Hijioka M, Kawabe K, Jensen R,

Keywords: Pancreatic neuroendocrine tumors, Chromogranin A, Chromogranin B,

#1177 An Isolated Abnormal Chromogranin B Is Associated with Pancreato-Duodenal NETs and the Presence of Liver Metastases

Introduction: Chromogranin B (CgB) is a soluble secretory protein like chromogranin A (CgA) that has been reported to be elevated in patients with neuroendocrine tumours (NETs) but is not routinely assessed.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Basuroy R, Sherwood R, Srirajaskanthan R, Ramage J,

Keywords: chromogranin A, chromogranin B, pancreas, duodenal, assay, liver metastases,

#844 Variation Between Chromogranin A Assays in the Diagnosis of Gastric Carcinoid Type 1

Introduction: Chromogranin A (CgA) is not very accurate for the diagnosis of gastric carcinoid type1 (GC1). Clinical interpretation of CgA results may be affected by the heterogeneity between CgA assays. The commercial CgA assay, DAKO (DAKO, Denmark A/S, Glostrup, Denmark) is an ELISA which recognizes a 23 kD C terminal fragment of CgA; the Imperial Supra-regional Assay Service radioimmunoassay (SAS Hammersmith Hospital, Imperial College, London) is a competitive radioimmunoassay raised against the whole pancreastatin molecule.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Rossi R, Martin N, Garcia-Hernandez J, Mandair D, Mohmaduves M,

Keywords: gastric carcinoid type 1, chromogranin A,

#601 Chromogranin A is a Sensitive Marker of Progression or Regression

Introduction: One of the most common is gastroenteropancreatic (GEP) NET of the pancreas, which constitute about 30% of all GEP NET. CgA is an excellent marker for NET and tumor volume and plasma CgA is suggested as the most reliable marker in follow-up of GEP but only few studies have been published.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Jensen K

Authors: Jensen K, Hilsted L, Andersen J, Mynster T, Rehfeld J,

Keywords: Chromogranin A, pancreatic neuroendocrine tumors, neuroendocrine tumors, computered tomography, RECIST 1.1, radioimmunoassay,

#591 Pancreastatin: A Predictive Neuroendocrine Tumor Marker

Introduction: Pancreastatin is a derived peptide of CgA. Pancreastatin has the potential to be a diagnostic and predictive tumor marker in detecting NETs.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Rustagi S, Warner R, Divino C,

Keywords: pancreastatin, NETs, CgA,